Oragenics Files S-1 for Potential Securities Offering
Ticker: OGEN · Form: S-1 · Filed: Dec 18, 2024 · CIK: 1174940
Sentiment: neutral
Topics: s-1, registration-statement, pharmaceuticals
TL;DR
Oragenics just filed an S-1, looks like they're prepping to sell more stock.
AI Summary
Oragenics Inc. filed an S-1 registration statement on December 18, 2024, indicating plans to offer securities. The company, incorporated in Florida with its principal executive offices in Sarasota, is involved in the pharmaceutical preparations industry. This filing is a standard step for companies looking to raise capital through the public markets.
Why It Matters
This S-1 filing signals Oragenics' intent to access public capital markets, which could fund future research, development, or expansion efforts for its pharmaceutical products.
Risk Assessment
Risk Level: medium — As an S-1 filing, it indicates a company seeking to raise capital, which inherently carries risks related to market conditions and the company's ability to execute its business plan.
Key Numbers
- 333-283927 — SEC File Number (Identifies the specific SEC registration)
- 59-3410522 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- ORAGENICS INC (company) — Registrant
- Florida (location) — State of incorporation
- 1990 Main Street, Suite 750 Sarasota, Florida 34236 (location) — Principal executive offices address
- Janet Huffman (person) — Chief Financial Officer and agent for service
- Mark A. Catchur (person) — Legal counsel
- Shumaker, Loop & Kendrick, LLP (company) — Legal counsel
- Ralph V. DeMartino (person) — Legal counsel
- ArentFox Schiff LLP (company) — Legal counsel
FAQ
What is the purpose of this S-1 filing?
The S-1 filing is a registration statement filed with the SEC to register securities for public sale, indicating Oragenics Inc.'s intent to raise capital.
When was this S-1 filing submitted?
The S-1 filing was submitted to the SEC on December 18, 2024.
Where are Oragenics Inc.'s principal executive offices located?
Oragenics Inc.'s principal executive offices are located at 1990 Main Street, Suite 750, Sarasota, Florida 34236.
Who is listed as the Chief Financial Officer and agent for service?
Janet Huffman is listed as the Chief Financial Officer and agent for service for Oragenics Inc.
What is Oragenics Inc.'s Standard Industrial Classification code?
Oragenics Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 4,468 words · 18 min read · ~15 pages · Grade level 17 · Accepted 2024-12-19 10:00:30
Key Financial Figures
- $0.001 — of one share of common stock, par value $0.001 per share (“Common Stock”)
- $0.33 — at an assumed public offering price of $0.33 per Unit, the last reported sale price
- $0 — d to the public in this offering, minus $0.001, and the exercise price of each Pre
- $0.339 — ncluding one Pre-Funded Warrant will be $0.339. (2) We will pay the Placement Agent
- $350,000 — cement agent fee, will be approximately $350,000. The delivery of the shares of Common
- $1,000,000 — acquisition, we paid Odyssey a total of $1,000,000 in cash, $500,000 of which was paid in
- $500,000 — Odyssey a total of $1,000,000 in cash, $500,000 of which was paid in October, 2023 and
- $6.9 billion — for concussion treatment was valued at $6.9 billion in 2020 and is forecast to reach $8.9 b
- $8.9 billion — illion in 2020 and is forecast to reach $8.9 billion by 2027, according to Grandview Researc
Filing Documents
- forms-1.htm (S-1) — 759KB
- ex5-1.htm (EX-5.1) — 22KB
- ex23-1.htm (EX-23.1) — 5KB
- ex23-2.htm (EX-23.2) — 5KB
- ex107.htm (EX-FILING FEES) — 20KB
- forms-1_001.jpg (GRAPHIC) — 4KB
- forms-1_002.jpg (GRAPHIC) — 12KB
- ex5-1_001.jpg (GRAPHIC) — 21KB
- 0001493152-24-050649.txt ( ) — 863KB
USE OF PROCEEDS
USE OF PROCEEDS 19 DIVIDEND POLICY 19 CAPITALIZATION 20
DESCRIPTION OF CAPITAL STOCK
DESCRIPTION OF CAPITAL STOCK 22
DESCRIPTION OF SECURITIES WE ARE OFFERING
DESCRIPTION OF SECURITIES WE ARE OFFERING 25 PLAN OF DISTRIBUTION 29 EXPERTS 32 LEGAL MATTERS 32 INCORPORATION BY REFERENCE 32 WHERE YOU CAN FIND MORE INFORMATION 34 ABOUT THIS PROSPECTUS We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under “Where You Can Find More Information.” You should carefully read this prospectus as well as additional information described under “Incorporation of Certain Information by Reference,” before deciding to invest in our securities. You should rely only on the information contained in this prospectus. We have not, and the Placement Agent has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you, and we take no responsibility for any other information others may give you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. We are not making an offer to sell these securities in any jurisdiction where an offer or sale is not permitted. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. The information incorporated by reference or provided in this prospectus contains statistical data and estimates, including those relating to market size and competitive position of the markets in which we participate, that we obtained from our o